Key result
Poor SGLT-2i adherence linked to ~4.1-fold higher mortality in heart failure with diabetes.
Why the study?
It was unknown whether the timing of SGLT-2i initiation prior to index HF diagnosis and subsequent medication adherence affect outcomes in patients with HF and diabetes.
Does the timing of SGLT-2 inhibitor initiation prior to heart failure diagnosis and medication adherence (proportion of days covered) after diagnosis impact all-cause mortality in patients with heart failure and type 2 diabetes?
Cohort (n=1,229,833)
Yes
Does the timing of SGLT-2 inhibitor initiation prior to heart failure diagnosis and medication adherence (proportion of days covered) after diagnosis impact all-cause mortality in patients with heart failure and type 2 diabetes?
In patients with heart failure and type 2 diabetes, survival is maximized when SGLT-2 inhibitors are initiated more than a year prior to heart failure diagnosis and maintained with ≥90% adherence after diagnosis.
Answers are grounded in this paper and cite their sources.
Supports post-diagnosis adherence monitoring in diabetic HF patients; leaves open causal effects and pre-diagnosis initiation timing.
BACKGROUND: It is imperative to maintain the use of sodium-glucose cotransporter-2 inhibitors (SGLT-2is) in patients with diabetes both after the index diagnosis of heart failure (HF) and even prior to the index diagnosis of HF. We aimed to investigate whether timing of SGLT-2 is before the index diagnosis of HF, and second, adherence to SGLT-2is in the form of the proportion of days covered metric matter in patients with HF and diabetes. METHODS AND RESULTS: All-cause death up to 7 years were evaluated in HF with diabetes from the subgroup analysis of TRends-HF (TRends in Heart Failure in Türkiye). Patients with HF and diabetes, who were prescribed an SGLT-2i either before or after the index diagnosis of HF were identified, categorized according to duration of exposure before the index HF diagnosis and according to proportion of days covered after the index diagnosis of HF, and compared with nonusers. There were 1 229 833 patients with HF and diabetes in the cohort. A total of 247 987 were on an SGLT-2i and had available timing data, and 14.06% had SGLT-2i on board before the index HF diagnosis. Median duration of SGLT-2i exposure before the index HF diagnosis was 417 days. Prognosis was the best among patients with diabetes who were prescribed an SGLT-2i before the index diagnosis of HF with an exposure more than median duration. Of note, among patients who were prescribed an SGLT-2i after the index HF diagnosis; there was a numerically graded increase in all-cause mortality rate such that a >10% decrease in SGLT-2i proportion of days covered was associated with a 59% increase in all-cause death (hazard ratio, 1.21-2.09). CONCLUSIONS: Regardless of time or adherence, SGLT-2is offer a remarkable all-cause death benefit to patients with HF and diabetes. SGLT-2is' all-cause death benefit for patients with HF and diabetes was greatest when it was prescribed before the HF index diagnosis. Poor adherence to SGLT-2is was associated with worsening survival in patients with HF and diabetes following the diagnosis of index HF.
No takes yet. Share an insight, caveat, or question.
Yılmaz et al. (2025) conducted a cohort in Heart failure and type 2 diabetes (n=1,229,833). SGLT-2 inhibitor (dapagliflozin or empagliflozin) prescription timing (before vs after index HF diagnosis) and adherence (proportion of days covered, PDC) vs. SGLT-2i nonusers, or patients with higher SGLT-2i adherence (PDC >=80% or >=90%) was evaluated on All-cause death up to 7 years (for PDC <80% vs >=80% in the propensity score-matched cohort after index HF diagnosis) (HR 4.07, 95% CI 3.66-4.52). Poor SGLT-2i adherence after heart failure diagnosis was associated with a 4.07-fold increased risk of all-cause mortality in patients with diabetes and HF.
Synapse has enriched 10 related papers. Consider them for comparative context: